DEXILANT Drug Patent Profile

Which patents cover Dexilant, and what generic alternatives are available?

Dexilant is a drug marketed by Takeda Pharms Usa and is included in two NDAs. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty patent family members in thirty-one countries.

The generic ingredient in DEXILANT is dexlansoprazole. There are seventeen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dexlansoprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dexilant

A generic version of DEXILANT was approved as dexlansoprazole by PH HEALTH on April 19^th, 2017.

Summary for DEXILANT

International Patents:	120
US Patents:	8
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DEXILANT

Paragraph IV (Patent) Challenges for DEXILANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DEXILANT	Delayed-release Capsules	dexlansoprazole	30 mg	022287	1	2010-11-30

US Patents and Regulatory Information for DEXILANT

DEXILANT is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009	AB	RX	Yes	No
Takeda Pharms Usa	DEXILANT SOLUTAB	dexlansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	208056-001	Jan 26, 2016		DISCN	Yes	No			Y
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009	AB	RX	Yes	No					Y
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009	AB	RX	Yes	No			Y

International Patents for DEXILANT

See the table below for patents covering DEXILANT around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2550626
Japan	5124267
Japan	5756548
Denmark	1553929

Supplementary Protection Certificates for DEXILANT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1129088	122014000036	Germany		PRODUCT NAME: KRISTALLINE FORM DES (R)-2-(((3-METHYL-4-(2,2,2-TRIFLUORETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAOLS; NAT. REGISTRATION NO/DATE: 87192.00.00 87193.00.00 87194.00.00 87195.00.00 20131118 FIRST REGISTRATION: SCHWEDEN 47911 47912 47913 47914 20130919
1129088	1490004-7	Sweden		PRODUCT NAME: DEXLANSOPRAZOL; REG. NO/DATE: 47912, 47913, 47914 20130919
1129088	PA2014014,C1129088	Lithuania		PRODUCT NAME: DEXLANSOPRAZOLUM; REGISTRATION NO/DATE: LT/1/13/3415/001 - LT/1/13/3415/004, 2013 10 31 LT/1/13/3416/001 - LT/1/13/3416/004 20131031
1129088	2014/008	Ireland		PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for DEXILANT

Last updated: February 3, 2026

---

Executive Summary

Dexilant (dexlansoprazole) is a proton pump inhibitor (PPI) used primarily to treat gastroesophageal reflux disease (GERD). As of 2023, the drug faces a complex market landscape characterized by increasing competition, patent expirations, and shifting healthcare policies. Despite challenges, Dexilant remains a relevant product, with potential opportunities driven by emerging markets and evolving therapeutic uses.

This report provides a comprehensive assessment of the investment outlook for Dexilant, analyzing key market dynamics, financial trajectories, and strategic factors influencing its future performance.

---

1. Product Overview and Market Position

Attribute	Details
Generic Name	Dexlansoprazole
Brand Name	Dexilant
Therapeutic Class	Proton Pump Inhibitor (PPI)
Indications	GERD, erosive esophagitis, pathological hypersecretory conditions
Launch Year	2009 (by Takeda Pharmaceuticals)

Market Share (2022):
Dexilant held approximately 11% of the PPI segment in the U.S., ranking behind dominant players such as omeprazole (Prilosec, 25%), esomeprazole (Nexium, 20%), and pantoprazole (Protonix, 18%).

Patent Landscape:
Patents covering Dexilant expired in 2018, leading to the proliferation of generic versions which now command a significant share.

---

2. Market Dynamics

2.1 Competitive Landscape

Competitors	Market Share (2022)	Notable Features	Entry Status
Omeprazole (Prilosec)	25%	First-generation PPI	Patent expired (2010)
Esomeprazole (Nexium)	20%	S-enantiomer, improved pharmacokinetics	Patent expired (2014)
Pantoprazole (Protonix)	18%	Widely used, IV formulation	Patent expired (2014)
Lansoprazole	8%	Common OTC availability	Patent expired (2010)
Dexilant	11% (pre-expiry)	Dual-action formula	Patent expired (2018)

The reduction in Dexilant's exclusivity has resulted in price erosion and loss of market share to generics.

2.2 Regulatory and Patent Considerations

• Patent expiry: 2018 in the U.S., leading to increased generics.
• Regulatory approvals: Generic manufacturers gained FDA approval within months of patent expiry, intensifying price competition.
• Regulatory barriers for biosimilars: Not applicable since Dexilant is not biologic, thereby easing the entry of chemical generics.

2.3 Market Trends and Drivers

Trend	Impact	Data/Source
Rising GERD prevalence	Expanding patient base	2021, CDC estimates 20% adult prevalence in the U.S.
Increasing adoption of OTC PPIs	Revenue shifts to OTC	OTC sales reached $5.8B in 2022 (IBISWorld)
Growing demand in emerging markets	Untapped markets	CAGR in APAC and LATAM: 7-9% (GlobalData)
Concerns about PPI safety (e.g., CKD)	Potential regulatory restrictions	FDA warnings on long-term PPI use

---

3. Financial Trajectory and Investment Outlook

3.1 Revenue Trends Post-Patent Expiry

Year	Estimated Revenue (USD billion)	Comments
2017	1.6	Peak pre-expiry; high-prescription share
2018	1.2	Patent expiry; onset of generic competition
2019	0.8	Volume decline; price erosion
2020	0.7	Market stabilization
2021	0.6	Further generic penetration
2022	0.55	Reduced brand contribution

Generic erosion accounts for ~60-70% revenue decline since 2018.

3.2 Cost Structure and Margin Impact

Aspect	Level	Notes
R&D expenses	~$50M/year	Minimal; primarily lifecycle management
Manufacturing costs	Moderate	Economies of scale achieved pre-generic entry
Pricing erosion	15-25% annually	Due to generics
Gross margins	Previously 65-70%	Now compressed to approx. 40-45%

3.3 Future Projections (2023-2028)

Scenario	Revenue Estimate (USD billion)	Growth Rate	Key Assumptions
Conservative	0.35	-5% annually	Continued generic competition, no new indications
Moderate	0.55	4% annually	Growth driven by emerging markets, OTC sales, new indications
Optimistic	0.75	8% annually	Expansion into new indications, market share gains

Forecasts are subject to regulatory changes, patent litigations, and market entry of competitors.

3.4 Potential Strategic Opportunities

• Line extensions: Developing formulations for additional indications like H. pylori eradication.
• Market diversification: Expanding into emerging markets with higher growth potential.
• Switching to OTC: Capitalizing on OTC availability to sustain sales.
• Partnerships: Licensing deals for novel formulations or delivery systems.

---

4. Key Comparative Analysis

Parameter	Dexilant	Nexium	Protonix	Generics (e.g., Omeprazole)
Year of launch	2009	1999	1998	2010s
Patent expiry	2018	2014	2014	2010s
Peak annual revenue	~$1.6B (2017)	~$6.2B (2013)	~$600M (pre-expiry)	Varies, high volume
Current market share	11% (pre-generic)	Leading regimens	Declining	Dominant in OTC

---

5. Strategic Investment Considerations

Focus Area	Implication	Risk/Opportunity
Patent litigation	Prolongs exclusivity	Legal costs, uncertainty
Market expansion	Access to high-growth regions	Regulatory hurdles
Product innovation	New formulations/delivery	R&D investment risk
Pricing strategies	Maintaining margin	Competition pressure
Regulatory environment	Safety concerns	Potential restrictions

---

6. Conclusion & Market Outlook

Despite the patent loss in 2018, Dexilant retains a foothold through brand loyalty and evolving formulations, but faces significant headwinds from generic competition.

Key drivers of future revenue include:

• Expansion into emerging markets with higher growth.
• Strategic use of OTC channels.
• Development of new indications and formulations.

Long-term profitability is contingent on innovation and market diversification. Investors should weigh the declining brand revenue against emerging opportunities and the potential for lifecycle management strategies.

---

7. Key Takeaways

• Patent expiry significantly reduced Dexilant’s market share, with revenues halving since 2017.
• Market competitors and generics dominate the PPI segment, exerting downward pressure on prices.
• Emerging markets and OTC channels offer growth avenues, but face regulatory and reimbursement uncertainties.
• Product lifecycle management through new indications and formulations is essential for future revenue stabilization.
• Regulatory and safety concerns may impact market access and prescribing practices.

---

8. FAQs

Q1: What are the primary factors impacting Dexilant’s sales post-patent expiry?
A: Increased generic competition, price erosion, and shifting prescribing habits toward OTC PPIs and alternative therapies are primary factors reducing sales.

Q2: Are there ongoing patent litigations that could restore exclusivity?
A: As of 2023, no active patent disputes are publicly reported. Patent challenges mostly concluded by 2018, with exclusivity ending.

Q3: Can Dexilant regain market share through new indications?
A: Potentially, yes. Expanding approval for additional indications like H. pylori or other acid-related conditions could support growth, but regulatory approval and market adoption are hurdles.

Q4: How significant is the opportunity in emerging markets?
A: Very significant; CAGR estimates range from 7-9%. Increasing GERD prevalence and OTC demand in Asia, Latin America, and Africa present substantial growth potential.

Q5: What strategies should investors monitor for Dexilant’s future?
A: Watch for lifecycle management initiatives, new formulation approvals, market entry of competitors, and shifts in global healthcare policies impacting PPIs.

---

References

1. IBISWorld Report: Proton Pump Inhibitors Market, 2022.
2. GlobalData: Pharmaceutical Market Outlook 2022-2027.
3. CDC: Adult GERD Prevalence Estimates, 2021.
4. FDA: PPI safety communication, 2020.
5. Takeda Pharmaceuticals Annual Reports: 2018–2022.

Note: All data and projections are estimates based on publicly available information as of Q1 2023 and are subject to change with market development.